Citations

Clear

9383 citation(s) found for "Thomas, PS".

Breast Cancer Risk Reduction and Membrane-Bound Catechol O -Methyltransferase Genetic Polymorphisms
Zhang, Jianping , Hildebrandt, Michelle, Wang, Liewei , Fredericksen, Zachary, Sellers, Thomas A. , Miller, William H. , Dixon, J. Michael , Brauch, Hiltrud , Eichelbaum, Michel , Justenhoven, Christina , Hamann, Ute , Ko, Yon, Brüning, Thomas , Chang‐Claude, Jenny , Wang‐Gohrke, Shan , Schaid, Daniel J. , Weinshilboum, Richard M. , Ji, Yuan , Olson, Janet E. , Ingle, James N. , Weinshilboum, Richard M. , Brauch, Hiltrud

Mayo Clinic

Cancer Research | July 16, 2008 | Volume: 68 | Issue: 14 | Pages: 5997-6005

10.1158/0008-5472.can-08-0043 | PMID 18632656 Get It

Abstract Catechol O-methyltransferase (COMT)-catalyzed methylation of catecholestrogens has been proposed to play a protective role in estrogen-induced genotoxic carcinogenesis. We have taken a comprehensive approach to test the hypothesis that genetic variation in COMT might influence breast cancer risk. Fifteen COMT single nucleotide polymorphisms (SNPs) selected on the basis of in-depth resequencing of the COMT gene were genotyped in 1,482 DNA samples from a Mayo Clinic breast cancer case control study. Two common SNPs in the distal promoter for membrane-bound (MB) COMT, rs2020917 and rs737865, were associated with breast cancer risk reduction in premenopausal women in the Mayo Clinic study, with allele-specific odds ratios (OR) of 0.70 [95% confidence interval (CI), 0.52–0.95] and 0.68 (95% CI, 0.51–0.92), respectively. These two SNPs were then subjected to functional genomic analysis and were genotyped in an additional 3,683 DNA samples from two independent case control studies (GENICA and GESBC). Functional genomic experiments showed that these SNPs could up-regulate transcription and that they altered DNA-protein binding patterns. Furthermore, substrate kinetic and exon array analyses suggested a role for MB-COMT in catecholestrogen inactivation. The GENICA results were similar to the Mayo case control observations, with ORs of 0.85 (95% CI, 0.72–1.00) and 0.85 (95% CI, 0.72–1.01) for the two SNPs. No significant effect was observed in the GESBC study. These studies showed that two SNPs in the COMT distal promoter were associated with breast cancer risk reduction in two of three case control studies, compatible with the results of functional genomic experiments, suggesting a role for MB-COMT in breast cancer risk. [Cancer Res 2008;68(14):5997–6005]
IGF-I, IGFBP-3, and IGF-I/IGFBP-3 Ratio: No Association with Incident Colorectal Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study
Max, Joshua, Ogunseitan, Adeboye, Vierkant, Robert A. , Pollak, Michael J., Sellers, Thomas A. , Virtamo, Jarmo, Cerhan, James R. , Pollak, Michaël , Limburg, Paul J. , Stolzenberg‐Solomon, Rachael Z. , Pollak, Michael J., Albanes, Demetrius , Cerhan, James R , Vierkant, Robert A , Pollak, Michael N

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 15, 2008 | Volume: 17 | Issue: 7 | Pages: 1832-1834

10.1158/1055-9965.epi-08-0345 | PMID 18628438 Get It

Performance of Amplified DNA in an Illumina GoldenGate BeadArray Assay
Cunningham, Julie M. , Sellers, Thomas A. , Schildkraut, Joellen M. , Fredericksen, Zachary S., Vierkant, Robert A. , Kelemen, Linda E. , Gadre, Madhura K., Phelan, Catherine M., Meyer, Jeffrey G., Pankratz, V. Shane , Goode, Ellen L. , Huang, Yifan , Vierkant, Robert A

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 15, 2008 | Volume: 17 | Issue: 7 | Pages: 1781-1789

10.1158/1055-9965.epi-07-2849 | PMID 18628432 Get It

Abstract Whole genome amplification (WGA) offers a means to enrich DNA quantities for epidemiologic studies. We used an ovarian cancer study of 1,536 single nucleotide polymorphisms (SNPs) and 2,368 samples to assess performance of multiple displacement amplification (MDA) WGA using an Illumina GoldenGate BeadArray. Initial screening revealed successful genotyping for 93.4% of WGA samples and 99.3% of genomic samples, and 93.2% of SNPs for WGA samples and 96.3% of SNPs for genomic samples. SNP failure was predicted by Illumina-provided designability rank, %GC (P ≤ 0.002), and for WGA only, distance to telomere and Illumina-provided SNP score (P ≤ 0.002). Distance to telomere and %GC were highly correlated; adjustment for %GC removed the association between distance to telomere and SNP failure. Although universally high, per-SNP call rates were related to designability rank, SNP score, %GC, minor allele frequency, distance to telomere (P ≤ 0.01), and, for WGA only, Illumina-provided validation class (P < 0.001). We found excellent concordance generally (>99.0%) among 124 WGA:genomic replicates, 15 WGA replicates, 88 replicate aliquots of the same WGA preparation, and 25 genomic replicates. Where there was discordance, it was across WGA:genomic replicates but limited to only a few samples among other replicates suggesting the introduction of error. Designability rank and SNP score correlated with WGA:genomic concordance (P < 0.001). In summary, use of MDA WGA DNA is feasible; however, caution is warranted regarding SNP selection and analysis. We recommend that biological SNP characteristics, notably distance to telomere and GC content (<50% GC recommended), as well as Illumina-provided metrics be considered in the creation of GoldenGate assays using MDA WGA DNA. (Cancer Epidemiol Biomarkers Prev 2008;17(7):1781–9)
Integrating Physicians, Researchers and Engineers—60Years of Medical Device Innovation at Mayo Clinic
Horne, April E., Bennet, Kevin A., Buntrock, Nathan C., Halovsen, Thomas G., Wehde, Mark

Mayo Clinic

Journal of Medical Devices | July 10, 2008 | Volume: 2 | Issue: 2 | Pages: No page available

10.1115/1.2924269 Get It

Medical innovation is often delayed by the difficulty in developing cooperation among practicing physicians, academics and medical device developers. In Rochester, Minnesota, the Mayo Clinic Division of Engineering has excelled at integrating these specialties, facilitating medical device innovation for the past 60years. In 1948, Mayo Clinic combined an instrument shop with an engineering design services team and created the Division of Engineering. This enabled a unique partnership between physicians, researchers, and product developers. Early innovations from this team include the Mayo heart-lung machine, cardiac monitoring, advances in aero-medicine, surgical stereotaxy, and early transfusion equipment. Today, the Mayo Division of Engineering consists of mechanical, chemical, electrical, biomedical, and software engineers, machinists, and a scientific glass-blower. The division works in close collaboration with project proponents (primarily physicians) within the clinical environment to analyze problems, propose designs, and deliver a clinical solution. From custom 3-D models for support pre-surgical planning to endoscopic heart valve repair devices, the team identifies opportunities and delivers systems that can be quickly translated into medical practice.
Nomenclature of Robotic Procedures in Urology
Castle, Erik P., Lee, David I. , Thomas, Raju , Ahlering, Thomas E.

Mayo Clinic

Journal of Endourology | July 9, 2008 | Volume: 22 | Issue: 7 | Pages: 1467-1470

10.1089/end.2008.0197 | PMID 18613788 Get It

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Rassenti, Laura Z., Jain, Sonia , Keating, Michael J. , Wierda, William G. , Grever, Michael R. , Byrd, John C. , Brown, Jennifer R. , Greaves, Andrew, Rai, Kanti R., Byrd, John C. , Kay, Neil E. , Gribben, John G. , Neuberg, Donna , He, Feng , Rai, Kanti R., Kipps, Thomas J. , Byrd, John C

Mayo Clinic

Blood | June 25, 2008 | Volume: 112 | Issue: 5 | Pages: 1923-1930

10.1182/blood-2007-05-092882 | PMID 18577710 Get It

AbstractLeukemia-cell expression of ZAP-70, CD38, or unmutated immunoglobulin heavy chain variable region genes (U-IGHV) each is associated with aggressive disease in patients with chronic lymphocytic leukemia (CLL). To assess the relative strength of each marker, we defined thresholds for designating a case as positive for CD38 or ZAP-70 in a test cohort of 307 patients and used these data-defined criteria to stratify patients in an independent cohort of 705 patients. Multivariable analysis revealed that ZAP-70 was the strongest risk factor. Knowledge of the IGHV mutation status or CD38 did not improve our ability to predict the time to first treatment except for ZAP-70–negative cases, which could be segregated into 2 groups of intermediate-risk or low-risk disease based on whether they expressed unmutated or mutated IGHV. ZAP-70 maintained its high relative prognostic value for the subset of patients with early-stage, asymptomatic disease, including patients evaluated within 1 year of diagnosis. Although it is premature to recommend therapy based on these risk factors, patients with ZAP-70–positive CLL cells should be monitored closely for disease progression as they have a median time from diagnosis to requiring initial therapy by standard criteria of approximately 3 years.
Neonatal Thyroid Function After Administration of IV Iodinated Contrast Agent to 21 Pregnant Patients
Atwell, Thomas D. , Lteif, Aida, Brown, Douglas L. , McCann, Mark, Townsend, Jane E., LeRoy, Andrew J.

Mayo Clinic

American Journal of Roentgenology | June 18, 2008 | Volume: 191 | Issue: 1 | Pages: 268-271

10.2214/ajr.07.3336 | PMID 18562757 Get It

Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis
Verstovšek, Srđan , Tefferi, Ayalew , Cortes, Jörge E. , O’Brien, Susan , Garcia‐Manero, Guillermo , Pardanani, Animesh , Akin, Cem , Faderl, Stefan, Manshouri, Taghi , Thomas, Deborah A. , Kantarjian, Hagop M. , Cortes, Jorge , Verstovsek, Srdan , Akin, Cem , Kantarjian, Hagop

Mayo Clinic

Clinical Cancer Research | June 16, 2008 | Volume: 14 | Issue: 12 | Pages: 3906-3915

10.1158/1078-0432.ccr-08-0366 | PMID 18559612 Get It

Abstract Purpose: Molecular characterization of Philadelphia chromosome–negative (Ph−) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-Abl TK than imatinib in vitro, significantly inhibiting wild-type KIT and platelet-derived growth factor receptor β TKs, and is active against cells carrying the mutant KIT-D816V gene. Experimental Design: In this phase 2, open-label study, the efficacy of dasatinib (140 mg/d) was investigated in 67 patients with various Ph− myeloid disorders, including SM (n = 33; 28 KIT-D816V positive). Results: The overall response rate to dasatinib in patients with SM was 33%. Only two patients, one with SM-myelofibrosis and one with SM-chronic eosinophilic leukemia, achieved complete response (elimination of mastocytosis) lasting for 5 and 16 months, respectively. Both patients were negative for KIT-D816V mutation, had low tryptase levels, abnormal WBC counts, and anemia, and had failed prior therapy with erythropoietin. Additional nine SM patients had symptomatic response, lasting 3 to 18+ months. Complete responses were achieved in two other patients (acute myeloid leukemia and hypereosinophilic syndrome). No responses were observed among patients with myelodysplastic syndromes and primary myelofibrosis. The majority of adverse events were grade 1/2. Conclusion: These data show that dasatinib therapy may benefit a selected group of SM patients, primarily by improving their symptoms, but it does not eliminate the disease in the patients with KIT-D816V mutation.
Familial and Perceived Risk of Breast Cancer in Relation to Use of Complementary Medicine
Myers, Cynthia D., Jacobsen, Paul B. , Frost, Marlene H., Cerhan, James R. , Sellers, Thomas A. , Huang, Yifan , Patten, Christi A. , Cerhan, James R

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 16, 2008 | Volume: 17 | Issue: 6 | Pages: 1527-1534

10.1158/1055-9965.epi-08-0028 | PMID 18541615 Get It

Abstract Aim: To examine the use of complementary and alternative medicine (CAM) by women with varying levels of familial and perceived risk of breast cancer with the goal of preventing breast cancer. Methods: Cross-sectional data on CAM use were collected on 2,198 women (mean age, 63 years) personally unaffected by breast cancer in the Minnesota Breast Cancer Family Study. CAM use was compared across women at high, moderate, or average risk based on family history, as well as across categories of perceived risk of breast cancer. CAM use was also examined in relation to screening and general health behaviors, worry about breast cancer, and optimism. Results: Half (49.5%) of the women reported using at least one CAM modality with the intent of preventing breast cancer. Univariate analyses indicated that greater overall CAM use was related to greater perceived risk (P = 0.018), more general health behaviors (P < 0.0001), more breast cancer screening behaviors (P = 0.0002), greater optimism (P = 0.0002), and higher educational attainment (P < 0.0001). Multivariate analysis revealed that general health behaviors (P < 0.0001), education (P = 0.0027), and optimism (P = 0.037) were significant predictors of CAM use when in the same model with perceived risk and breast cancer screening behaviors. Conclusions: Many women use CAM with the goal of preventing breast cancer. General health-promoting behaviors, education, and optimism predict CAM use. Evidence-based guidance is needed for the public and health care providers on the potential and limitations of specific CAM approaches to affect cancer risk. (Cancer Epidemiol Biomarkers Prev 2008;17(6):1527–34)
Factors Associated with Breast Cancer Prevention Communication between Mothers and Daughters
Frost, Marlene H., Vierkant, Robert A. , Petersen, Larra R., Rock, Emily, Clark, Lara P. , Vachon, Celine M. , Fredericksen, Zachary S., Sellers, Thomas A. , Cerhan, James R. , Sinicrope, Pamela S. , Brockman, Tabetha A. , Patten, Christi A. , Vachon, Celine M. , Cerhan, James R , Vierkant, Robert A

Mayo Clinic

Journal of Women's Health | June 13, 2008 | Volume: 17 | Issue: 6 | Pages: 1017-1023

10.1089/jwh.2007.0497 | PMID 18554093 Get It

Objective: Mother-daughter communication may be a potential pathway between family history and cancer prevention behavior. We examined the degree to which mothers reported providing advice on breast cancer prevention to their daughters, the content of such advice, and correlates of providing such advice. Methods: Data were collected via a mailed questionnaire to 1773 women from 355 families in the Minnesota Breast Cancer Family Study. Women were asked whether or not they had provided advice to their daughters on what they should do to prevent breast cancer. An additional open-ended question asked them to describe the types of advice they had provided. Results: Nine hundred seventy-six (55%) of the women reported providing breast cancer prevention advice to their daughters. The most frequent types of advice were to have a mammogram (51%), perform breast self-examination (BSE) (39%), have a clinical breast examination (CBE) (30%), and maintain a healthy lifestyle (21%). From multivariate logistic regression, older age ( p < 0.001), having a personal history of breast cancer ( p < 0.001), higher degree of breast cancer worry/concern ( p < 0.001), engaging in a higher number of health-promoting behaviors ( p < 0.001), and ever performing a BSE ( p = 0.04) were factors independently associated with the provision of advice. Analyses accounting for sample nonindependence did not change our results. Conclusions: Breast cancer prevention behaviors were associated with providing advice. By better understanding the pathways through which breast cancer family history is associated with screening mammography and other prevention behaviors, researchers can develop more effective, tailored prevention interventions at the family level.